Geospatial Health as Interdisciplinary Research for Health Care Reform and Planning. Markku Tykkyläinen – Mikko Pyykönen – Sami Sieranoja – Pasi Fränti – Tiina Laatikainen
University of Eastern Finland, IMPRO, Joensuu
Geospatial costs of delivering health in FinlandSTN IMPRO
IMPRO project's presentation at Understanding Present and Future Public Service Delivery Costs, a kick-off workshop hosted by OECD, Brussels, June 28th, 2019.
Spending reviews - Stefan Kiss, Slovak RepublicOECD Governance
This presentation was made by Stefan Kiss, Slovak Republic, at the 3rd Health Systems Joint Network meeting for Central, Eastern and South-eastern European Countries held in Vilnius, Lithuania, on 25-26 April 2019
Impact of an EMIS search to prioritise care home residents for a pharmacist l...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Impact of an EMIS search to prioritise care home residents for a pharmacist led medication review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Understanding How Markets & State Action Shape Costs & Prices of Healthcare i...Revathy Raju
Understanding How Markets & State Action Shape Costs & Prices of Healthcare in Post-globalization India: A Study of High-end Imaging Services in Kerala
Official Representative of the International Research ofthe Mission for European and International Relation and Cooperation (MREIC) ofthe French National Health Insurance Fund (CNAMTS)
Geospatial costs of delivering health in FinlandSTN IMPRO
IMPRO project's presentation at Understanding Present and Future Public Service Delivery Costs, a kick-off workshop hosted by OECD, Brussels, June 28th, 2019.
Spending reviews - Stefan Kiss, Slovak RepublicOECD Governance
This presentation was made by Stefan Kiss, Slovak Republic, at the 3rd Health Systems Joint Network meeting for Central, Eastern and South-eastern European Countries held in Vilnius, Lithuania, on 25-26 April 2019
Impact of an EMIS search to prioritise care home residents for a pharmacist l...Health Innovation Wessex
The Health Innovation Network Polypharmacy programme is working with healthcare professionals to address problematic polypharmacy by supporting easier identification of patients at potential risk from harm from multiple medications.
Our evidence-based polypharmacy Action Learning Sets (ALS) are being rolled out across England to support GPs, pharmacists and other healthcare professionals who undertake prescribing or medication reviews to understand the complex issues around stopping inappropriate medicines safely.
To drive and accelerate changes in practice, delegates complete a quality improvement project to address problematic polypharmacy in their workplace. This poster summary, Impact of an EMIS search to prioritise care home residents for a pharmacist led medication review, can be viewed here.
For more information about the polypharmacy programme, please visit https://thehealthinnovationnetwork.co.uk/programmes/medicines/polypharmacy/
Understanding How Markets & State Action Shape Costs & Prices of Healthcare i...Revathy Raju
Understanding How Markets & State Action Shape Costs & Prices of Healthcare in Post-globalization India: A Study of High-end Imaging Services in Kerala
Official Representative of the International Research ofthe Mission for European and International Relation and Cooperation (MREIC) ofthe French National Health Insurance Fund (CNAMTS)
Các nguyên tắc sửa đổi về submit dữ liệu điện tử để apply cho các thuốc mới lưu hành tại Nhật Bản. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU
The role of health technology assessment bodies in the value of cancer care i...Francois MAIGNEN
This presentation details the role of European HTA bodies in the value of new cancer therapies in Europe. The presentation also describes the NICE scientific advice activities and the activities of the HTA / regulatory parallel advice.
Economic Evaluation of the Electronic Palliative Care Coordination System (EP...NHS Improving Quality
As part of our work on End of Life Care, an Economic Evaluation of the Electronic Palliative Care Coordination System (EPaCCS) Early Implementer Sites was undertaken. The evaluation includes quantifying impact from implementation, co-ordination of care and the economic case for EPaCCS.
Review of Marie Skłodowska-Curie actions unit costs in preparation for Horizo...Mantas Pupinis
The objective of this study was to carry out a review of the MSCA unit costs system in line with the Commission’ policy priorities and Horizon Europe proposal, and to determine the future eligible researcher and institutional unit costs for each Marie Skłodowska-Curie Action.
Accessibility of health services - transporting people and servicesSTN IMPRO
IMPRO:n järjestämässä Paikkatieto sote-uudistuksen tukena -seminaarissa 8.10.2019 Helsingin yliopistolla Oulun yliopiston Tiina Lankila ja Tiina Huotari esittelivät tuloksiaan terveydenhuollon saavutettavuus -tutkimuksistaan. Esityksessä keskityttiin erityisesti palveluiden mobiliteettiin sekä asiakkaiden liikkumiseen.
More Related Content
Similar to Geospatial Health as Interdisciplinary Research for Health Care Reform and Planning
Các nguyên tắc sửa đổi về submit dữ liệu điện tử để apply cho các thuốc mới lưu hành tại Nhật Bản. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU
The role of health technology assessment bodies in the value of cancer care i...Francois MAIGNEN
This presentation details the role of European HTA bodies in the value of new cancer therapies in Europe. The presentation also describes the NICE scientific advice activities and the activities of the HTA / regulatory parallel advice.
Economic Evaluation of the Electronic Palliative Care Coordination System (EP...NHS Improving Quality
As part of our work on End of Life Care, an Economic Evaluation of the Electronic Palliative Care Coordination System (EPaCCS) Early Implementer Sites was undertaken. The evaluation includes quantifying impact from implementation, co-ordination of care and the economic case for EPaCCS.
Review of Marie Skłodowska-Curie actions unit costs in preparation for Horizo...Mantas Pupinis
The objective of this study was to carry out a review of the MSCA unit costs system in line with the Commission’ policy priorities and Horizon Europe proposal, and to determine the future eligible researcher and institutional unit costs for each Marie Skłodowska-Curie Action.
Accessibility of health services - transporting people and servicesSTN IMPRO
IMPRO:n järjestämässä Paikkatieto sote-uudistuksen tukena -seminaarissa 8.10.2019 Helsingin yliopistolla Oulun yliopiston Tiina Lankila ja Tiina Huotari esittelivät tuloksiaan terveydenhuollon saavutettavuus -tutkimuksistaan. Esityksessä keskityttiin erityisesti palveluiden mobiliteettiin sekä asiakkaiden liikkumiseen.
Paikkatiedon hyödyntäminen terveydenhuollon uudistuksessa ja arvioinnissaSTN IMPRO
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena seminaarissa 8.10.2019 THL:n sote-arvioinnista vastaava projektipäällikkö Kimmo Parhiala esitteli paikkatiedon tuomia mahdollisuuksia sote-järjestelmään.
Hallitusohjelma ja sote-palvelujärjestelmäSTN IMPRO
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena seminaarissa 8.10.2019 sosiaali- ja terveysministeriön lääkintäneuvos Timo Keistinen esitteli uuden hallituksen sote-suunnitelmaa. Keistinen on mukana sote-uudistuksen valmistelussa.
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena -seminaarissa 8.10.2019 Oulun yliopiston dosentti Harri Antikainen esitteli paikkatiedon hyödyntämistä sote-alan päätöksenteossa. Esityksen keskiössä erityisesti palveluiden optimointi ja kustannustehokkuus.
Walking and cycling in accessibility researchSTN IMPRO
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena seminaarissa 8.10.2019 Helsingin yliopiston Digital Geography Labin tohtorikoulutettava Elias Willberg esitteli matka-aikojen optimointia. Tutkimuksessaan hän keskittyy palveluiden saavutettavuuteen pyöräilyn ja kävelyn näkökulmasta.
Optimizing Geographic Access to Health CareSTN IMPRO
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena seminaarissa 8.10.2019 Pohjois-Carolinan yliopiston Eric Delmelle esitteli Yhdysvalloissa tekemäänsä tutkimusta terveyspalvelujen optimoinnista paikkatietoa hyödyntäen.
IMPROn järjestämässä Paikkatieto sote-uudistuksen tukena seminaarissa 8.10.2019 Pohjois-Carolinan yliopiston Eric Delmelle esitteli nousevia teemoja terveysmaantieteen saralla. Esityksen keskiössä on uusien teknologioiden ja niiden datan hyödyntäminen terveysmaantieteessä.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Dehradun ❤CALL Girls 8901183002 ❤ℂall Girls IN Dehradun ESCORT SERVICE❤
Geospatial Health as Interdisciplinary Research for Health Care Reform and Planning
1. 15.4.2019 1
Geospatial Health as Interdisciplinary Research
for Health Care Reform and Planning
1
Annual Meeting , American Association of Geographers,
Washington DC, 3-7. April 2019
Markku Tykkyläinen – Mikko Pyykönen – Sami Sieranoja – Pasi Fränti
– Tiina Laatikainen
University of Eastern Finland, IMPRO, Joensuu
https://www.stnimpro.fi/
https://www.stnimpro.fi/contact-information/
https://www.uef.fi/web/geospatial-health
AAG, April 5th, 2019, 3.05 PM- 4:45 PM, Marshall South, Marriot Mezzane Level
2. 2
Aims of IMPRO - Improved knowledge
base and service optimisation to support
health and social services reform
• Quality of care
- better outcomes of care more cost-
efficiently
- equal outcomes
- new ways of care
• Need of care – where and how?
• Cost savings: care & patients
• Optimal spatial allocation of services
• To sum up: Allocation of scarce
resources over space cost-efficiently to
produce better care in the region
Research related to IMPRO’s geospatial approach:
Oulu/Geography/(WP1): Geography of health and well-
being as focus area in research of the dept. (WP1)
Joensuu/Geographies/Research group: Geospatial
Health, Geoinformatics. (WP4)
Joensuu: School of Computing (CS): optimization tools.
(WP6)
HEL/Aalto University/ Institute of Healthcare
Engineering, Management and Architecture
(Economics): costs, data bases & research. (WP5)
Kuopio/Institute of Public Health and Clinical Nutrition:
“heavy users” of health care and social services. (WP3)
HEL/National Instit. for Health and Welfare THL (Health
sc): emergency and specialist care services. (WP2)
Hospital districts: databases, registers; indicators of care
Focus on
chronic diseases
AAG 2019
3. Reform of health and social services
• At the moment the 311
municipalities are responsible
for organizing health and
social services. This
responsibility will be
transferred to about 18-22
new regions and cities when
the health and social services
reform will be implemented in
the early 2020s on.
Study area:
North Karelia
3
4. AAG 2019 4
Where ”geospatial health” comes
from?
Operations
Research
(complex
systems, CP,
LP, netw.)
Spatial
Statistics
(n-dim. space,
regr., hot
spots)
Computational
sciences
(algorithms, clust.,
sim., progr.,
db)
GPS,
georef info
(coordinates,
orientation) GIScience/
Geoinformatics
(db, analysis,
rem sens)
Health
Sciences
Spatial
economics
(space-time
dynamics)
1990s-
1950-60s
1990s
Geospatial
Health
Spatial
analysis
(geogr., reg.
sc.; math.
space)
1990s-
NEGEarly location
and spatial
economic
theoretizations
1900-40s
5. Atrial fibrillation medications
Drugs:
Warfarin
+ lab
visits (up
20 p.a.)
Or new
DOAC
The locations of health
care centers (labs) are
on the map on the right.
Warfarin should be
used near the health
care centers.
Now the consumption
patterns of alternative
drugs are NOT cost-
efficient at all (on the
map on the left).
Warfarin should not be
used in the peripheries.
Derivation of the market areas of two alternative drugs – varfarin vs. DOAC (Direct-Acting Anticoagulants)
AAG 2019 5
6. • Drugs: Warfarin &
DOAC
• Number of lab visits
up 20 annually if
Warfarin is used
• Out-of-pocket costs
Fixed costs
= DOAC
W is
cheaper
W lab
Market areas - a bird's eye
view
DOAC
W 2
W 1
Least-cost optimization of AF atrial fibrillation
treatment
- derivation of market areas
TCwcv1
Areawcv1Areawcv2
cv1
cv2
Pw
TCwcv2
Distance d
Gradients of
the total costs
of Warfarin to
the patient
A
€
AreaDOAC
The sizes of market areas are influenced by drug prices and additionally from one to
two laboratory visits if the patient uses W.
TCwcv2
TCwcv1
cDOAC
TCDOAC
6
7. Variables: Distance between home and health care center
Travel time between home and health care center
Travel modes: car
bus
taxi
walking
Parameter Description Value Used in Analysis
VOT The value of time based on average hourly gross wage of North
Karelia.
10.3 €/h
P The productivity coefficient of patient. Working time is valued as 100
percent of VOT and leisure time of a retired person is valued as 35
percent of VOT.
Working persons: 1
Retired persons: 0.35
Tm The time spent in the INR monitoring visit. 20 min = 0.33 h
Td The time spent for dose adjustment of warfarin after monitoring. 10 min = 0.167 h
Tp The time spent for private car parking. 5 min = 0.083 h
Tt The service time of taxi. 5 min = 0.083 h
Tbw1 The waiting time in a bus stop. 7 min = 0.117 h
Tbw2 The walking time to bus stop. 5 min = 0.083 h
VOCc The vehicle operating cost for private car. 0.45 €/km
VOCt The vehicle operating cost for taxi. 1.59€/km
Ft The initial fare paid for the journey with taxi. 5.9 €
Fb The fare paid for the journey with bus. 3.8 €
Sb The average speed of bus. 30 km/h
Sw The average speed of walking. 3.5 km/h
Cwar The annual cost of warfarin after reimbursement. 25.5 €
CNOAC The annual cost of NOAC after reimbursement. Dabigatran and Apixaban 369.3 €
Rivaroxaban and Edoxaban 338.3 €
FREQ The frequency of monitoring visits per year. From 6 to 30
15.4.2019 AAG 2019 7
Mikko Pyykönen
8. The least-cost market areas of anticoagulation therapies for working persons. Three market area
classes (colored by the shades of grey) having 10, 14 and 18 annual INR monitoring visits indicate
where warfarin is most affordable. DOAC therapy brings about the lowest costs outside of the
respective warfarin market areas.
Mikko Pyykönen
mikko.pyykonen@uef.fi
AAG 2019
Warfarin is
most
affordable
to use in
centers.
8
9. Resulting clusters (2 out of 30)
Gout
Cardiomyopathy
Heart failure
Diverticular disease of intestine
Chronic kidney disease (CKD)
2.5
3.6 4.9
3.7
4.6
4.1
2.4 1.9
Asthma
Sleep disorders
Abnormalities of breathing
Overweight and obesity
Hypertensive heart disease
3.6 2.0
1.6
3.3
2.8
2.4
2.0
5.1
2.6
2.2
= observed/expected
("correlation")
weights
Sami Sieranoja
Total number of patients = 9149
Clustering: Maximize the sum of
weights/pairwise links
Multimorbidity
AAG 2019 9
10. Conclusions
• Currently different diagnoses are treated separately
• Treating a related diseases together can be more cost effective
• In training new doctors, could optimize skill sets based on how
diagnoses are connected
Asthma
Sleep disorders
Abnormalities of breathing
Overweight and obesity
Hypertensive heart disease
3.6 2.0
1.6
3.3
2.8
2.4
2.0
5.1
2.6
2.2
Sami Sieranoja
sami.sieranoja@uef.fi
AAG 2019 10
11. Multimorbidity
AAG 2019 11
Local optima
Global optimum
Treatment
outcomes per
cost by
multimorbid
patient *)
Unknown, more cost-efficient
outcomes
• How do we reach globally
optimal, more cost efficient
results in multimorbidity care?
• So, do we simulate different
combinations?
• Any good examples?
*) it indicates cost savings compared to usual care practices